AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
42.55
-0.04 (-0.09%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close42.59
Open42.60
Bid0.00 x 1800
Ask0.00 x 800
Day's Range42.42 - 42.79
52 Week Range34.38 - 43.30
Volume2,971,691
Avg. Volume5,002,944
Market Cap106.914B
Beta (3Y Monthly)0.46
PE Ratio (TTM)50.06
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.40 (3.29%)
Ex-Dividend Date2019-02-28
1y Target EstN/A
Trade prices are not sourced from all markets
  • AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes
    Zacks18 hours ago

    AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes

    AstraZeneca's (AZN) diabetes drug gets approval in Europe for type-1 diabetes as an adjunct to insulin in patients with a BMI greater or equal to 27 kg/m2.

  • Reutersyesterday

    EU approves AstraZeneca's drug for adjunct use in Type-1 diabetes

    Forxiga can now be used along with insulin in patients with Type-1 diabetes and a Body Mass Index (BMI) of 27 or more when insulin alone has not been able to control blood sugar levels, the company said https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-approved-in-europe-for-type-1-diabetes22032019.html. Type-1 diabetes is a chronic condition in which the pancreas produces little or no insulin hormone. Farxiga or Forxiga, as the drug is known outside the United States, is one of AstraZeneca's top ten drugs by sales.

  • Reuters4 days ago

    J&J to record $700 million charge related to abandoned drug program

    (Reuters) - Johnson & Johnson on Thursday said https://www.sec.gov/Archives/edgar/data/200406/000020040619000016/a20190321alios8-k.htm it will record a nearly $700 million (£536.4 million) impairment charge ...

  • Reuters4 days ago

    J&J to record $700 mln charge related to abandoned drug program

    Johnson & Johnson on Thursday said https://www.sec.gov/Archives/edgar/data/200406/000020040619000016/a20190321alios8-k.htm it will record a nearly $700 million impairment charge in the first quarter of ...

  • Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market
    Zacks5 days ago

    Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market

    Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.

  • The Zacks Analyst Blog Highlights: Las Vegas Sands, Phillips 66, AstraZeneca, Hilton and AutoZone
    Zacks5 days ago

    The Zacks Analyst Blog Highlights: Las Vegas Sands, Phillips 66, AstraZeneca, Hilton and AutoZone

    The Zacks Analyst Blog Highlights: Las Vegas Sands, Phillips 66, AstraZeneca, Hilton and AutoZone

  • Top Stock Reports for Las Vegas Sands, Phillips 66 & AstraZeneca
    Zacks6 days ago

    Top Stock Reports for Las Vegas Sands, Phillips 66 & AstraZeneca

    Top Stock Reports for Las Vegas Sands, Phillips 66 & AstraZeneca

  • The Zacks Analyst Blog Highlights: Merck, Adobe, Broadcom, AstraZeneca and Ross Stores
    Zacks7 days ago

    The Zacks Analyst Blog Highlights: Merck, Adobe, Broadcom, AstraZeneca and Ross Stores

    The Zacks Analyst Blog Highlights: Merck, Adobe, Broadcom, AstraZeneca and Ross Stores

  • PhaseBio Stock Up on Positive Data From PB2452 Phase I Study
    Zacks7 days ago

    PhaseBio Stock Up on Positive Data From PB2452 Phase I Study

    PhaseBio's (PHAS) stock skyrockets on positive data from an early-stage study evaluating PB2452, showing immediate and sustained reduction in bleeding risk in patients taking AstraZeneca's Brilinta.

  • Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer
    Zacks7 days ago

    Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer

    Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

  • Why You Should Buy ABBV Stock for Income and Value
    InvestorPlace7 days ago

    Why You Should Buy ABBV Stock for Income and Value

    Today, I'd like to discuss the outlook for AbbVie (NYSE:ABBV), the $116-billion-market-cap biopharmaceutical stock, whose shares have been in a downtrend for almost a year and have especially been hammered following its earning report of Jan. 25.Source: Shutterstock * Top 7 Service Sector Stocks That Will Pay You to Own Them There could be further price volatility and weakness in the ABBV stock price in the coming weeks, pushing it toward the low-$70's or even mid-$60's level. However, it is a company with robust growth prospects and respectable dividends that may deserve a place in a diversified portfolio.Therefore, if you already own AbbVie shares, you might want to hold your position. That said, within the parameters of your portfolio allocation and risk/return profile, you may consider placing a stop loss at about 5-7% below the current price point. Expect nearer-term trading to be choppy at best.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIf you are an experienced investor in the options market, you may want to protect your portfolio with a covered call or possibly a put option spread with a 3-month time horizon. If you do not yet hold ABBV, you may want to wait several weeks to buy into the stock at the next dip.With all of that in mind, here's a deeper look into at AbbVie stock. A Hiccup in the Robust Fundamental StoryIn 2013, Abbott Laboratories (NYSE:ABT) spun off its research-based pharmaceuticals business, creating AbbVie, an independent biopharmaceutical company. Abbott decided to retain the branded generic pharmaceuticals, diagnostics, medical devices and nutrition.Meanwhile, AbbVie took control of the development and commercialization of a range of brands, including Humira, its flagship drug used to treat autoimmune diseases, Imbruvica, which differentiates between cancer cells and regular cells, and Synthroid, a replacement for a hormone normally produced by the thyroid gland.The company's financials and growth metrics over the past five years have been impressive and ABBV was in a strong financial position heading into 2019, with hopes of a higher share price during the first quarter.However, in January, AbbVie's fourth-quarter earnings release weighed heavily on the stock. For starters, the company missed the consensus on revenue. Its earnings per share of $1.90 was below the expected number of $1.94. The next day, the stock fell by 6% and that decline has intensified over the past two months.ABBV's quarterly report also showed that the international sales of Humira fell by almost 15% year over year, mostly as a result of 'biosimilar' competition in Europe, which makes up three-quarters of the overseas Humira business. In October 2018, its patent in the European Union (E.U) expired.The U.S. Food and Drug Administration (FDA) refers to biosimilars as "highly similar to an FDA-approved biological product … [that has] no clinically meaningful differences in terms of safety and effectiveness." Although Wall Street had already known about this sales decline in Europe, when coupled with the other question marks in the earnings report, it was enough to increase the selling pressure on the stock.It is also possible that investors got worried about the potential fall in Humira revenue when the drug comes off patent in 2023 in the U.S. It is important to emphasize that AbbVie's revenue from the drug will not decline to nothing when the biosimilars hit the market in 2023. What will most likely happen is that as the company's pricing power decreases, the revenue will also gradually decline.Therefore, many analysts feel that ABBV shares offer value and that any bad news that is specific to Humira is already baked into the stock price. Value PlayWhen markets penalize biopharma stocks, it can take some time for them to recover. However, for patient long-term investors, the returns can be significant -- especially when the company boasts several other current drugs, as well promising ones in the pipeline.At present, AbbVie's other major products include: * AndroGel, a testosterone replacement therapy. * Creon, a pancreatic enzyme therapy to treat exocrine pancreatic insufficiency. * Duopa and Duodopa, gels to treat Parkinson's disease. * Viekira Pak, which treats chronic hepatitis C. * Zinbryta, to treat multiple sclerosis.Analysts are also expecting a slew of new products in 2020, such as next-generation immunology drugs. These drugs and others that are being developed and commercialized, highlight how impressive the potential growth story could be in the next few years.ABBV trades at a trailing price-to-earnings (P/E) ratio of 21. This number is rather modest when compared with the P/E ratios of several competitors, including AstraZeneca (NYSE:AZN) with a P/E of 49.9, Pfizer (NYSE:PFE) with a P/E of 25.2, and Merck (NYSE:MRK) with a P/E of 34.8. Reinvesting the Sweet Dividend Yield of ABBV stockIncome investors know that they can compound their returns through reinvesting dividends from high-yielding shares. AbbVie also offers investors a healthy dividend yield of about 5.4%, another reason why I believe the stock belongs in a capital-growth portfolio.Since its spin-off from Abbott Laboratories in 2013, ABBV has increased dividends every year -- a trend that is likely to continue. The next dividend payment is scheduled for May 15, 2019, with an ex-dividend date of April 12.It would not be wrong to call AbbVie a cashflow machine; as of Dec. 31, the company had a free cash flow of $3.27 billion. This strength not only gives shareholders conviction that the dividends are safe, but also provides the company with enough flexibility to, for example, make acquisitions to offset any further Humira revenue decline (especially in the U.S. when the drug comes off patent in 2023). The Bottom Line on AbbVie StockLike most biopharma stocks, AbbVie is a high-momentum stock. In other words, when the broader markets go up or when the company's earnings beat expectations, both investors and momentum traders tend to hit the "buy" button fast, expecting superior gains within days or weeks.However, if markets suffer a decline or if the company cannot keep up with the rising expectations, investors' risk appetite decreases fast and these stocks can fall much harder than less volatile stocks. * 7 Financial Stocks to Invest In Today The market has punished Abbvie stock since the start of the year. The stock may continue to struggle through much of 2019. However, patient ABBV bulls will probably be proven right to believe in the management's commitment to create shareholder value and to further grow the company both organically and through acquisitions. In the meantime, they can continue to collect high dividends.As of this writing, Tezcan Gecgil did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Financial Stocks to Invest In Today * 7 Single-Digit P/E Stocks With Massive Upside * 5 Chip Stocks on the Rise Compare Brokers The post Why You Should Buy ABBV Stock for Income and Value appeared first on InvestorPlace.

  • Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?
    Zacks7 days ago

    Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?

    Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?

  • Benzinga7 days ago

    The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 18) AstraZeneca plc (NYSE: AZN )(received orphan drug ...

  • Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
    Zacks7 days ago

    Novartis' (NVS) Alcon Acquired PowerVision for $285 Million

    Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.

  • Top Research Reports for Merck, Adobe & Broadcom
    Zacks8 days ago

    Top Research Reports for Merck, Adobe & Broadcom

    Top Research Reports for Merck, Adobe & Broadcom

  • Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth
    Zacks8 days ago

    Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth

    Inovio's (INO) most advanced candidate, VGX-3100 vaccine, is advancing well. Heavy reliance on partners for funds to develop its pipeline candidates is a persistent concern.

  • AstraZeneca Up This Year on New Drugs & Pipeline Progress
    Zacks8 days ago

    AstraZeneca Up This Year on New Drugs & Pipeline Progress

    AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

  • 3 Dividend Stocks That Should Pay You the Rest of Your Life
    Motley Fool9 days ago

    3 Dividend Stocks That Should Pay You the Rest of Your Life

    These dividend stocks could send you checks for a lifetime.

  • 3 Top Diabetes Stocks to Watch in March
    Motley Fool10 days ago

    3 Top Diabetes Stocks to Watch in March

    Keep your eyes on these three hot diabetes stocks this month.

  • Benzinga10 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

    Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support. Here are some key catalysts that can move biotech stocks in the ...

  • Guardant Health (GH) Q4 2018 Earnings Conference Call Transcript
    Motley Fool10 days ago

    Guardant Health (GH) Q4 2018 Earnings Conference Call Transcript

    GH earnings call for the period ending December 31, 2018.

  • AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat, Revenues Lag
    Zacks11 days ago

    AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat, Revenues Lag

    AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in Q4. However, revenues fall shy of estimates.

  • Merck's Keytruda Gets EU Approval for Difficult Lung Cancer
    Zacks11 days ago

    Merck's Keytruda Gets EU Approval for Difficult Lung Cancer

    Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.

  • Here's Why Momentum Investors Will Love Astrazeneca (AZN)
    Zacks12 days ago

    Here's Why Momentum Investors Will Love Astrazeneca (AZN)

    Does Astrazeneca (AZN) have what it takes to be a top stock pick for momentum investors? Let's find out.